Skip to main content
SpringerLink
Log in

A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

To assess the effects of GM-CSF in patients with myelodysplasia, a total of 101 patients with refractory anemia (RA), RA with ringed sideroblasts (RARS), and RA with an excess of blasts provided that the percentage of blasts in the bone marrow did not exceed 10% (RAEB) were enrolled in the EORTC Leukemia Cooperative Group study 06885. They were randomized to receive two daily subcutaneous injections of rhGM-CSF (mammalian, glycosylated, Sandoz/Schering-Plough) at a daily dose of either 108μg glycoprotein (group I) or 216μg glycoprotein (group II) for 8 weeks. Response was defined as an increase in Hb (> 2.5 g%), neutrophil count (more than 100%), or platelet count (more than 100%) without progression of the disease. After exclusion of 19 patients who did not meet the entry criteria, 82 were evaluated. Fifty-four patients (66%) responded (27 of 42 patients in group I and 27 of 40 in group II). Progressive disease was seen in two patients of group I and in four of group II. Two of the latter developed leukemia. All responses were reflected in the granulocytic series. In two patients platelet numbers also increased. Cytogenetic analysis, successfully performed in 43 cases, showed that 14 of 16 patients with normal karyotypes responded, compared with 14 of 27 patients with abnormal karyotypes (p=0.008). In some cases GM-CSF was reduced in dose or discontinued prematurely due to side effects so that only 35% of all evaluable patients finished 8 weeks of treatment without a change of dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Antin JH, Smith BR, Holmes W, Rosenthal DS (1988) Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 72: 705–713

    PubMed  Google Scholar 

  2. Bennett JM, Catovsky D, Daniel DT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) The French-American-British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 181–199

    PubMed  Google Scholar 

  3. Breslow N (1984) Comparison of survival curves. In: Buyse M, Staquet M, Sylvester R (eds) Cancer clinical trials: methods and practice. Oxford University Press, Oxford, pp 381–406

    Google Scholar 

  4. De Witte T, Muus P, De Pauw B, Haanen C (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66: 831–837

    PubMed  Google Scholar 

  5. Estey EH, Kurzrock P, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU (1991) Effects of low doses of recombinant human granulocy-temacrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 77: 291–295

    PubMed  Google Scholar 

  6. Ganser A, Völkers B, Greher J, Ottmann OG, Walter F, Becher R, Bergmann L, Schulz G, Hoelzer D (1989) Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes — a phase I/II trial. Blood 73: 31–37

    PubMed  Google Scholar 

  7. Kerkhofs H, Hermans J, Haak HL, Leeksma CH (1987) Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br Haematol 65: 73–81

    Google Scholar 

  8. Kobayashi Y, Okabe T, Ozawa K, Chiba S, Hino M, Miyazono K, Urabe A, Takaku F (1989) Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. Am J Med 86: 178–182

    PubMed  Google Scholar 

  9. Koeffler HP (1986) Preleukaemia. Clin Haematol 15: 829–849

    PubMed  Google Scholar 

  10. Lagakos SW, Pocock SJ (1984) Randomization and stratification in cancer clinical trials: an international survey. In: Buyse M, Staquet M, Sylvester R (eds): Cancer clinical trials: methods and practice. Oxford University Press, Oxford, pp 276–286

    Google Scholar 

  11. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59: 425–433

    PubMed  Google Scholar 

  12. Negrin RS, Haeuber DH, Nagler A, Olds LC, Donlon T, Souza LM, Greenberg PL (1989) Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 110: 976–984

    PubMed  Google Scholar 

  13. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76: 36–43

    PubMed  Google Scholar 

  14. Peto J (1984) The calculation and interpretation of survival curves. In: Buyse M, Staquet M, Sylvester R (eds) Cancer clinical trials: methods and practice. Oxford University Press, Oxford, pp 361–380

    Google Scholar 

  15. Schuster MW, Larson RA, Thompson JA, Coiffier B, Bennett JM, Israel RJ (1990) Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): results of a multi-center randomized controlled trial. Blood 76: 10: 318

    Google Scholar 

  16. Siegel S (1956) Non-parametric statistics for behavioral sciences. McGraw-Hill, New York

    Google Scholar 

  17. Suciu S, Kuse R, Weh HJ, Hossfeld DK (1990) Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 44: 15–26

    PubMed  Google Scholar 

  18. Thompson JA, Lee DJ, Kidd P, Rubin E, Kaufmann J, Bonnem EM, Fefer A (1989) Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics and hematological effects. J Clin Oncol 7: 629–637

    PubMed  Google Scholar 

  19. Tricot G, Vlietinck R, Boogaerts MA, Hendrickx B, De Wolf-Peeters C, Van den Berghe, Verwilghen RL (1985) Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 60: 19–32

    PubMed  Google Scholar 

  20. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1551

    PubMed  Google Scholar 

  21. Yuo A, Kitagawa S, Okabe T, Urabe A, Komatsu Y, Itoh S, Takaku F (1987) Recombinant human granulocyte colonystimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia. Blood 70: 404–411

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Leiden University Medical Center, NL-2300, RC Leiden, The Netherlands

    R. Willemze

  2. Sandoz Pharma Ltd, Basel, Switzerland

    A. C. Stern

Authors
  1. R. Willemze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. van der Lely
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Zwierzina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Suciu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Solbu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Gerhartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Labar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Visani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. E. Peetermans
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P. Stryckmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P. Fenaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H. L. Haak
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M. M. Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. E. Baumelou
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M. Baccarani
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. F. Mandelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. B. Jaksic
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. A. Louwagie
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. A. Thyss
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. M. Hayat
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. F. de Cataldo
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. A. C. Stern
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. R. Zittoun
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

EORTC Leukemia Cooperative Group

Rights and permissions

Reprints and permissions

About this article

Cite this article

Willemze, R., van der Lely, N., Zwierzina, H. et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Ann Hematol 64, 173–180 (1992). https://doi.org/10.1007/BF01696219

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01696219

Key words

Search

Navigation